Expression of immunohistochemical markers in primary and metastatic malignant melanoma: A comparative study in 70 patients using a tissue microarray technique

Keyphrases

• Metastatic Melanoma 100%
• Immunohistochemical Markers 100%
• Metastatic Site 100%
• Tissue Microarray 100%
• Microarray Experiment 100%
• Primary Malignant Melanoma 100%
• Melanoma 75%
• Metastasis 75%
• B-cell Lymphoma 2 (Bcl-2) 50%
• Primary Tumor 50%
• Primary Lesion 50%
• Melanoma Cells 50%
• Thyroid Transcription factor-1 (TTF-1) 50%
• Tyrosinase 50%
• S100 Proteins 50%
• Primary Melanoma 50%
• Aberrant Expression 50%
• Antigenic Shift 50%
• Cytokeratin 50%
• Epithelial Membrane Antigen 50%
• CD117 50%
• Immunophenotyping 25%
• Immunoreactivity 25%
• Carcinoembryonic Antigen 25%
• Metastatic Lesions 25%
• Antigen Expression 25%
• HMB-45 25%
• Melanocytic Markers 25%
• Vimentin 25%
• Oncogene Expression 25%
• Tissue Core 25%
• CD99 25%
• Aberrant Marker Expression 25%

Medicine and Dentistry

• Tissue Microarray 100%
• Melanoma 100%
• Metastatic Carcinoma 60%
• Primary Tumor 40%
• Melan A 40%
• Homeobox Protein Nkx 2.1 40%
• Tyrosinase 40%
• S-100 Protein 40%
• Epithelial Membrane Antigen 40%
• Cytokeratin AE1 40%
• Antigenic Shift 40%
• Carcinoembryonic Antigen 20%
• Immunoreactivity 20%
• Oncogene 20%
• HMB-45 20%
• Metastatic Melanoma 20%
• Vimentin 20%
• Immunophenotyping 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Melanoma 100%
• Primary Tumor 40%
• Tyrosinase 40%
• Protein S 100 40%
• Epithelial Membrane Antigen 40%
• Melan A 40%
• Homeobox Protein Nkx 2.1 40%
• Cytokeratin AE1 40%
• Carcinoembryonic Antigen 20%
• Metastatic Melanoma 20%
• Vimentin 20%